New data suggested that donanemab (Kisunla) sustained long-term benefits after a limited dosing period in a subgroup of people with early symptomatic Alzheimer's disease. Early Alzheimer's patients ...

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed more than 10,000 PET scans of patients from the IDEAS study. Measurement of Centiloids from ...

At early symptomatic stages of Alzheimer’s disease, amyloid immunotherapy taps the brakes on cognitive decline, but does not halt the disease. Many researchers think the full promise of plaque removal ...

Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer’s disease have had mixed results. We tested solanezumab, which targets monomeric amyloid, in a ...